Theseus Pharmaceuticals is committed to outsmarting cancer resistance by developing best-in-class, pan-variant kinase inhibitors, to shape the future of targeted oncology.
For more details on financing and valuation for Theseus Pharmaceuticals, register or login.
By registering, you agree to Forge’s Terms of Use. Already registered? Log in
THRX
7.35 as of 3/27/23
To read this article and more news on Theseus Pharmaceuticals, register or login.
